Jeremy Skillington, CEO of Poolbeg Pharma (POLB ), talks Vox Markets through the latest positive results of its lab-based, AI led analysis of its RSV drug candidates
00:28 Details of the latest results of lab-based analysis of RSV drug candidates.
01:24 How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery.
2:41 The importance of the data quality offered by human challenge models in lab-base analysis.
4:35 The growing importance of AI in drug discovery, and how Poolbeg’s leading position should open up partnering opportunities with biopharma groups.
Q&A: Poolbeg Pharma’s Jeremy Skillington on AI-led RSV breakthrough
Dec 20, 2023Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.